KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells $39,875.42 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Nicole Sweeny sold 1,489 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $26.78, for a total transaction of $39,875.42. Following the transaction, the insider owned 59,291 shares in the company, valued at approximately $1,587,812.98. The trade was a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Nicole Sweeny also recently made the following trade(s):

• On Friday, May 22nd, Nicole Sweeny sold 1,861 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $26.78, for a total transaction of $49,837.58.
• On Friday, April 17th, Nicole Sweeny sold 1,862 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $20.22, for a total transaction of $37,649.64.

KalVista Pharmaceuticals Trading Up 0.3%

NASDAQ KALV opened at $26.85 on Friday. The firm’s 50 day moving average price is $22.37 and its two-hundred day moving average price is $17.83. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -7.76 and a beta of -0.12. KalVista Pharmaceuticals, Inc. has a twelve month low of $9.83 and a twelve month high of $26.87. The company has a debt-to-equity ratio of 8.18, a quick ratio of 5.10 and a current ratio of 5.17.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The business had revenue of $40.86 million for the quarter, compared to the consensus estimate of $39.03 million. Equities analysts anticipate that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current year.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Parallel Advisors LLC lifted its stake in shares of KalVista Pharmaceuticals by 45.8% in the 1st quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 589 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at $55,000. Royal Bank of Canada lifted its stake in shares of KalVista Pharmaceuticals by 137.0% in the 1st quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company’s stock valued at $59,000 after purchasing an additional 1,686 shares during the last quarter. Finally, Truvestments Capital LLC lifted its stake in shares of KalVista Pharmaceuticals by 253.8% in the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,360 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. JonesTrading lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 30th. HC Wainwright lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the company from $37.00 to $27.00 in a research note on Friday, May 1st. Citizens Jmp lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Leerink Partners lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Finally, Wall Street Zen lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 21st. Three equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $30.60.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical?stage biotechnology company focused on the discovery and development of small?molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.